vs
弗雷斯特研究公司（FORR）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是IOVANCE BIOTHERAPEUTICS, INC.的1.2倍（$101.1M vs $86.8M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs -6.5%），弗雷斯特研究公司自由现金流更多（$-4.3M vs $-61.9M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs 0.5%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
FORR vs IOVA — 直观对比
营收规模更大
FORR
是对方的1.2倍
$86.8M
营收增速更快
IOVA
高出24.2%
-6.5%
自由现金流更多
FORR
多$57.6M
$-61.9M
两年增速更快
IOVA
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $86.8M |
| 净利润 | $-33.9M | — |
| 毛利率 | 56.7% | 67.4% |
| 营业利润率 | -36.6% | -84.7% |
| 净利率 | -33.5% | — |
| 营收同比 | -6.5% | 17.7% |
| 净利润同比 | -7941.4% | — |
| 每股收益（稀释后） | $-1.75 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRIOVA
| Q4 25 | $101.1M | $86.8M | ||
| Q3 25 | $94.3M | $67.5M | ||
| Q2 25 | $111.7M | $60.0M | ||
| Q1 25 | $89.9M | $49.3M | ||
| Q4 24 | $108.0M | $73.7M | ||
| Q3 24 | $102.5M | $58.6M | ||
| Q2 24 | $121.8M | $31.1M | ||
| Q1 24 | $100.1M | $715.0K |
净利润FORRIOVA
| Q4 25 | $-33.9M | — | ||
| Q3 25 | $-2.1M | $-91.3M | ||
| Q2 25 | $3.9M | $-111.7M | ||
| Q1 25 | $-87.3M | $-116.2M | ||
| Q4 24 | $432.0K | — | ||
| Q3 24 | $-5.8M | $-83.5M | ||
| Q2 24 | $6.3M | $-97.1M | ||
| Q1 24 | $-6.7M | $-113.0M |
毛利率FORRIOVA
| Q4 25 | 56.7% | 67.4% | ||
| Q3 25 | 60.0% | 43.0% | ||
| Q2 25 | 55.5% | 5.5% | ||
| Q1 25 | 55.9% | -0.8% | ||
| Q4 24 | 58.8% | 68.7% | ||
| Q3 24 | 60.5% | 46.2% | ||
| Q2 24 | 57.3% | -0.8% | ||
| Q1 24 | 54.9% | — |
营业利润率FORRIOVA
| Q4 25 | -36.6% | -84.7% | ||
| Q3 25 | 4.7% | -140.7% | ||
| Q2 25 | 6.2% | -189.8% | ||
| Q1 25 | -97.5% | -245.8% | ||
| Q4 24 | -0.5% | -117.5% | ||
| Q3 24 | -0.7% | -152.1% | ||
| Q2 24 | 9.3% | -327.6% | ||
| Q1 24 | -9.3% | -16464.6% |
净利率FORRIOVA
| Q4 25 | -33.5% | — | ||
| Q3 25 | -2.3% | -135.3% | ||
| Q2 25 | 3.5% | -186.2% | ||
| Q1 25 | -97.1% | -235.5% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -5.7% | -142.7% | ||
| Q2 24 | 5.2% | -312.2% | ||
| Q1 24 | -6.7% | -15800.8% |
每股收益（稀释后）FORRIOVA
| Q4 25 | $-1.75 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $0.20 | $-0.33 | ||
| Q1 25 | $-4.62 | $-0.36 | ||
| Q4 24 | $0.02 | $-0.24 | ||
| Q3 24 | $-0.30 | $-0.28 | ||
| Q2 24 | $0.33 | $-0.34 | ||
| Q1 24 | $-0.35 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $297.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.5M | $698.6M |
| 总资产 | $404.0M | $913.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FORRIOVA
| Q4 25 | $63.3M | $297.0M | ||
| Q3 25 | $65.1M | $300.8M | ||
| Q2 25 | $67.8M | $301.2M | ||
| Q1 25 | $75.6M | $359.7M | ||
| Q4 24 | $56.1M | $323.8M | ||
| Q3 24 | $62.8M | $397.5M | ||
| Q2 24 | $58.9M | $412.5M | ||
| Q1 24 | $61.4M | $356.2M |
股东权益FORRIOVA
| Q4 25 | $126.5M | $698.6M | ||
| Q3 25 | $157.7M | $702.3M | ||
| Q2 25 | $159.5M | $698.5M | ||
| Q1 25 | $147.4M | $767.9M | ||
| Q4 24 | $229.5M | $710.4M | ||
| Q3 24 | $234.3M | $773.5M | ||
| Q2 24 | $237.1M | $768.5M | ||
| Q1 24 | $230.9M | $680.0M |
总资产FORRIOVA
| Q4 25 | $404.0M | $913.2M | ||
| Q3 25 | $414.2M | $904.9M | ||
| Q2 25 | $436.0M | $907.4M | ||
| Q1 25 | $439.8M | $966.7M | ||
| Q4 24 | $503.9M | $910.4M | ||
| Q3 24 | $505.3M | $991.1M | ||
| Q2 24 | $524.2M | $964.3M | ||
| Q1 24 | $555.7M | $869.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $-61.9M |
| 自由现金流率自由现金流/营收 | -4.2% | -71.3% |
| 资本支出强度资本支出/营收 | 1.1% | 10.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $18.1M | $-336.2M |
8季度趋势，按日历期对齐
经营现金流FORRIOVA
| Q4 25 | $-3.2M | $-52.6M | ||
| Q3 25 | $1.2M | $-78.7M | ||
| Q2 25 | $-3.6M | $-67.4M | ||
| Q1 25 | $26.7M | $-103.7M | ||
| Q4 24 | $-1.8M | $-73.3M | ||
| Q3 24 | $264.0K | $-59.0M | ||
| Q2 24 | $-2.9M | $-98.4M | ||
| Q1 24 | $611.0K | $-122.3M |
自由现金流FORRIOVA
| Q4 25 | $-4.3M | $-61.9M | ||
| Q3 25 | $524.0K | $-89.5M | ||
| Q2 25 | $-4.2M | $-74.9M | ||
| Q1 25 | $26.1M | $-109.9M | ||
| Q4 24 | $-2.5M | $-77.5M | ||
| Q3 24 | $-223.0K | $-61.3M | ||
| Q2 24 | $-3.7M | $-98.9M | ||
| Q1 24 | $-815.0K | $-126.5M |
自由现金流率FORRIOVA
| Q4 25 | -4.2% | -71.3% | ||
| Q3 25 | 0.6% | -132.7% | ||
| Q2 25 | -3.8% | -124.9% | ||
| Q1 25 | 29.0% | -222.8% | ||
| Q4 24 | -2.3% | -105.1% | ||
| Q3 24 | -0.2% | -104.6% | ||
| Q2 24 | -3.1% | -317.9% | ||
| Q1 24 | -0.8% | -17685.3% |
资本支出强度FORRIOVA
| Q4 25 | 1.1% | 10.7% | ||
| Q3 25 | 0.7% | 16.1% | ||
| Q2 25 | 0.5% | 12.4% | ||
| Q1 25 | 0.7% | 12.6% | ||
| Q4 24 | 0.6% | 5.7% | ||
| Q3 24 | 0.5% | 3.9% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 1.4% | 583.4% |
现金转化率FORRIOVA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
